Angiogenesis Associated With Visceral and Subcutaneous Adipose Tissue in Severe Human Obesity

  1. Séverine Ledoux12,
  2. Isabelle Queguiner1,
  3. Simon Msika2,
  4. Sophie Calderari1,
  5. Pierre Rufat3,
  6. Jean-Marie Gasc1,
  7. Pierre Corvol1 and
  8. Etienne Larger14
  1. 1Institut National de la Santé et de la Recherche Médicale U833, Chaire de Médecine Expérimentale, Collège de France, Paris, France
  2. 2Centre de l’obésité, Hôpital Louis Mourier, Assistance Publique–Hopitaux de Paris (AP-HP), Faculté de Médecine Xavier Bichat, Université Paris 7, Paris, France
  3. 3Unité MSI-Département de Biostatistique, santé publique, et information médicale, Groupe Hospitalier Pitié-Salpetrière, AP-HP, Paris, France
  4. 4Universite Rene Descartes, Paris, France
  1. Corresponding author: Séverine Ledoux, severine.ledoux{at}lmr.aphp.fr

Abstract

OBJECTIVE—The expansion of adipose tissue is linked to the development of its vasculature. However, the regulation of adipose tissue angiogenesis in humans has not been extensively studied. Our aim was to compare the angiogenesis associated with subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) from the same obese patients in an in vivo model.

RESEARCH DESIGN AND METHODS—Adipose tissue samples from visceral (VAT) and subcutaneous (SAT) sites, obtained from 36 obese patients (mean BMI 46.5 kg/m2) during bariatric surgery, were layered on chick chorioallantoïc membrane (CAM).

RESULTS—Both SAT and VAT expressed angiogenic factors without significant difference for vascular endothelial growth factor (VEGF) expression. Adipose tissue layered on CAM stimulated angiogenesis. Angiogenic stimulation was macroscopically detectable, with engulfment of the samples, in 39% and was evidenced by angiography in 59% of the samples. A connection between CAM and adipose tissue vessels was evidenced by immunohistochemistry, with recruitment of both avian and human endothelial cells. The angiogenic potency of adipose tissue was not related to its localization (with an angiogenic stimulation in 60% of SAT samples and 61% of VAT samples) or to adipocyte size or inflammatory infiltrate assessed in adipose samples before the graft on CAM. Stimulation of angiogenesis by adipose tissue was nearly abolished by bevacizumab, which specifically targets human VEGF.

CONCLUSIONS—We have established a model to study the regulation of angiogenesis by human adipose tissue. This model highlighted the role of VEGF in angiogenesis in both SAT and VAT.

Footnotes

  • Published ahead of print at http://diabetes.diabetesjournals.org on 3 October 2008.

    Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted September 16, 2008.
    • Received December 22, 2007.
| Table of Contents

This Article

  1. Diabetes vol. 57 no. 12 3247-3257
  1. Online-Only Appendix
  2. All Versions of this Article:
    1. db07-1812v1
    2. 57/12/3247 most recent